Risk factor analysis for taxane-associated acute pain syndrome under the dexamethasone prophylaxis

Saito, Yoshitaka; Takekuma, Yoh; Kobayashi, Masaki; Sakamoto, Tatsuhiko; Yamashita, Hiroko; Sugawara, Mitsuru

Risk factor analysis for taxane-associated acute pain syndrome under the dexamethasone prophylaxis

Saito, Yoshitaka; Takekuma, Yoh; Kobayashi, Masaki et al.

Supportive care in cancer, 2021, 29, 8059-8067

Permalink : https://hdl.handle.net/2115/86277

このアイテムのアクセス数:609件（2026-08-18 18:30 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
R1. Manuscript] Saito et al. TAPS risk factor	pdf	496 KB	651

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/86277
タイトル	Risk factor analysis for taxane-associated acute pain syndrome under the dexamethasone prophylaxis
著者	Saito, Yoshitaka ; Takekuma, Yoh ; Kobayashi, Masaki ; Sakamoto, Tatsuhiko ; Yamashita, Hiroko ; Sugawara, Mitsuru
e-Rad_Researcher 00835001 著者名 Saito, Yoshitaka
e-Rad_Researcher 00396293 著者名 Takekuma, Yoh
e-Rad_Researcher 70431319 著者名 Kobayashi, Masaki
著者名 Sakamoto, Tatsuhiko
e-Rad_Researcher 70332947 著者名 Yamashita, Hiroko
e-Rad_Researcher 60332467 著者名 Sugawara, Mitsuru
言語	英語
キーワード	Taxane-associated acute pain syndrome (T-APS)
	Paclitaxel
	Docetaxel
	Dexamethasone (DEX)
	Arthralgia
	Myalgia
発行日	2021-07-06
出版者	Springer
収録物名	Supportive care in cancer
巻(号)	29
ページ	8059-8067
抄録	Purpose Taxane-associated acute pain syndrome (T-APS) reportedly occurs in approximately 70% of patients undergoing therapy. We have previously reported that additional dexamethasone (DEX) administration attenuates T-APS. The aim of this study was to reveal risk factor(s) associated with the incidence of T-APS under prophylactic DEX administration. Methods In total, 143 patients with breast cancer who received docetaxel (75 mg/m(2)) or paclitaxel (175 mg/m(2))-containing treatment regimens were enrolled. DEX (4-8 mg) was orally administered on days 2-4. Risk factors for the incidence of >= G2 and all-grade T-APS, as well as T-APS incidence between taxane-containing regimens in the first cycle, were retrospectively evaluated. Results Approximately 90% of the patients received taxanes for adjuvant or neoadjuvant chemotherapy. Overall, 55% of patients administered 4 mg DEX, whereas 45% received 8 mg DEX. Pegfilgrastim was administered in 27% of patients. Incidence of >= G2 and all-grade T-APS was 23.8%, and 69.2%, respectively. Univariate and multivariate analyses revealed that administration of pegfilgrastim is an independent risk factor for the incidence of >= G2 and all-grade T-APS; age younger than 55 years is also a risk factor for all-grade T-APS. Moreover, the incidence of >= G2 and all-grade T-APS was 45.5% and 81.8% in a paclitaxel regimen, and 22.0% and 68.2% in docetaxel-including regimens, respectively, revealing increased tendency with paclitaxel administration, with no significant differences. Conclusion Pegfilgrastim co-administration is an independent risk factor for >= G2 and all-grade T-APS, and age younger than 55 years is a risk factor of all-grade T-APS under prophylactic DEX administration.
資源タイプ	学術雑誌論文
出版タイプ	Accepted Manuscript
権利情報	This is a post-peer-review, pre-copyedit version of an article published in Supportive care in cancer. The final authenticated version is available online at: http://dx.doi.org/10.1007/s00520-021-06342-2
PISSN	0941-4355
関連情報 (isVersionOf)	出版社版DOI https://doi.org/10.1007/s00520-021-06342-2